Device
Superparamagnetic Iron Oxide
Superparamagnetic Iron Oxide is a medical device with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Not yet recruiting1
Recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
not_yet_recruiting133%
recruiting133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_3
Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II
NCT07552597
completedphase_1
Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide
NCT05359783
recruitingphase_2
Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients
NCT06169072
Clinical Trials (3)
Showing 3 of 3 trials
NCT07552597Phase 3
Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II
NCT05359783Phase 1
Sentinel Node Localization and Staging with Low Dose Superparamagnetic Iron Oxide
NCT06169072Phase 2
Sentinel Lymph Node Localisation With an Ultra-low Dose of Magtrace in Breast Cancer Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 3